Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Stroke

Volumn 38, Issue 12, 2007, Pages 3198-3204

  Amarenco, Pierre ^a   Goldstein, Larry B ^a   Szarek, Michael ^a   Sillesen, Henrik ^a   Rudolph, Amy E ^a   Callahan, Alfred ^a   Hennerici, Michael ^a   Simunovic, Lisa ^a   Zivin, Justin A ^a   Welch, K Michael A ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Lipids; Prevention; Statins; Stroke

Indexed keywords

ATORVASTATIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; BRAIN; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LIPIDS; MALE; MIDDLE AGED; RISK; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 36448964544     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.493106     Document Type: Article

References (10)

1. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
2. Amarenco P, Lavallée P, Touboul P-J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol. 2004;3:271-277.
3. Amarenco P, Labreuche J, Lavallée P, Touboul P-J. Statin in stroke prevention and carotid atherosclerosis: systematic review and meta-analysis. Stroke. 2004;35:2902-2909.
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
5. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke. 1997;28:2315-2320.
6. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
7. The SPARCL Investigators. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
8. The SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis. 2003;16:389-395.
9. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239.
10. Amarenco P, Moscowitz MA. The dynamics of statins. From event prevention to neuroprotection. Stroke. 2006;37:294-296.